Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Brufen arginine pseudoephedrine hydrochloride compound formulation

A technology of pseudoephedrine hydrochloride and pseudoephedrine, which is applied in the direction of anti-inflammatory agents, pill delivery, and pharmaceutical formulations, can solve the problems of gastrointestinal irritation and slow onset of action, and achieve improved water solubility, fast onset of action, and stable drug efficacy. lasting effect

Active Publication Date: 2004-12-29
杭州容立医药科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] But, because the ibuprofen in this composition is almost insoluble in water, pharmacokinetic parameter T max (The time to reach the maximum blood concentration) is 1.5-2h. Like other oral NSAIDs (non-steroidal anti-inflammatory drugs), the onset of action is relatively slow, and it has a certain stimulating effect on the gastrointestinal tract.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Brufen arginine pseudoephedrine hydrochloride compound formulation
  • Brufen arginine pseudoephedrine hydrochloride compound formulation
  • Brufen arginine pseudoephedrine hydrochloride compound formulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1: Preparation of ibuprofen arginine pseudoephedrine compound tablet

[0068] Prescription (per 1000 tablets):

[0069] Ibuprofen Arginine 370g

[0070] Pseudoephedrine Hydrochloride 30g

[0071] Lactose 37.5g

[0072] Starch 37.5g

[0073]Microcrystalline Cellulose 15g

[0074] 2% Povidone in water 25ml

[0075] Talc 2.8g

[0076] Magnesium Stearate 0.9g

[0077] Craft:

[0078] (1) Pass the original and auxiliary materials through an 80-mesh sieve respectively;

[0079] (2) get the recipe quantity of ibuprofen arginine and pseudoephedrine hydrochloride and mix with starch, then add lactose, microcrystalline cellulose and mix;

[0080] (3) Add 2% povidone aqueous solution to make soft material, dry at 70°C, add talc and magnesium stearate after 16 mesh granulation, mix well, measure the content of granules, and press into tablets.

Embodiment 2

[0081] Example 2: Preparation of ibuprofen arginine pseudoephedrine compound capsules

[0082] Prescription (per 1000 capsules):

[0083] Ibuprofen Arginine 570g

[0084] Pseudoephedrine Hydrochloride 30g

[0085] Hydroxypropylethylcellulose 10g

[0086] Starch 5g

[0087] Micro Powder Silica 5g

[0088] Craft:

[0089] (1) Take the recipe quantities of ibuprofen arginine and pseudoephedrine, hydroxypropyl ethyl cellulose, starch, and micropowder silica gel to pass through a 40-mesh sieve, and mix well.

[0090] (2) Capsules.

Embodiment 3

[0091] Example 3: Preparation of ibuprofen arginine pseudoephedrine compound sustained-release tablet

[0092] Prescription (per 1000 tablets)

[0093] Sustained release tablet core:

[0094] Ibuprofen Arginine 400g

[0095] Lactose 30g

[0096] HPMC 60g

[0097] (Hydroxypropylmethylcellulose)

[0098] Ethyl cellulose 20g

[0099] Magnesium Stearate 8.2g

[0100] Immediate release layer:

[0101] Ibuprofen Arginine 500g

[0102] Pseudoephedrine Hydrochloride 30g

[0103] Shading Layers:

[0104] Opadry 45g

[0105] Craft:

[0106] (1) according to the above-mentioned prescription, take 75% ethanol as a wetting agent, after the slow-release tablet core components are mixed uniformly according to the recipe quantity, make granules, add magnesium stearate to be a lubricant, and press the tablet to obtain the slow-release tablet core;

[0107] (2) the tablet core is added in the coating pot according to the recipe quantity and the immediate-release layer component is ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The compound preparation contains ibuprofen-arginine and pseudoephedrine or its pharmaceutically accedptable salt in the weight ratio of 1-40. The combination of ibuprofen with arginine results in raised water solubility of ibuprofen to increase the absorption rate in body and reduce the irritation to gastrointestinal tract. The compound preparation has fast, stable and lasting curative effect.

Description

(1) Technical field [0001] The present invention relates to a compound preparation containing ibuprofen arginine and pseudoephedrine or a pharmaceutically acceptable salt composition thereof. (2) Background technology [0002] Pseudoephedrine or pharmaceutically acceptable salts thereof (eg, pseudoephedrine hydrochloride, pseudoephedrine sulfate) are recognized by those skilled in the art as effective sympathomimetic drugs for the treatment of nasal congestion. Ibuprofen, a non-steroidal anti-inflammatory drug, is also known to have antipyretic, anti-inflammatory, and analgesic effects. Therefore, the oral composition containing both ibuprofen and pseudoephedrine or a pharmaceutically acceptable salt thereof is suitable for the treatment of headache, fever, sore throat, joint and limb muscle aches and pains caused by colds, allergic rhinitis, Nasal congestion, runny nose, sneezing and other symptoms. [0003] However, the ibuprofen in this composition is almost insoluble i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K9/22A61K9/48A61K9/52A61K31/198A61P11/02A61P11/04A61P29/00
Inventor 陆峰胡雅芳
Owner 杭州容立医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com